Bio Job Blog : Bio Jobs : Biotechnology Jobs : Biopharmaceutical Jobs : Bioscience, Biotech Jobs : Bio Job Blog : Biocareer : Bio-Business Training, Biotechnology Training : Jobs in Biology : Internships in Biology : Internships in Biotechnology

Johnson & Johnson announced today it would eliminate as many as 8,200 jobs, or 7% of its work force, to help the company cope with what it expects will be a slow economic recovery amid damped demand for drugs, medical devices and consumer products. J&J employs about 117, 000 workers globally. While the job cuts will be global, many losing their jobs will be outside of the US. 

J & J joins a growing list of pharmaceutical and life sciences companies that have announced new layoffs. Pfizer Inc., the world’s biggest drugmaker, plans to fire 19,000 workers following its acquisition of Wyeth and had already cut 10,000 positions since 2007. J&J began firing as many as 4,400 employees from its pharmaceutical and stent divisions in late 2007. Finally, Merck recently announced that it will be eliminating 16,000 workers after its merger with Schering Plough closes later this year.

J&J’s announcement is more bad news for New Jersey which is still reeling from the earlier loss of tens of thousands of pharmaceutical and life sciences jobs.

Until next time...

Good Luck and Good Job Hunting (forget New Jersey)

• Email This
• Print
• Comments (1)
• Trackbacks
• Share Link

According to a report yesterday, Roche is reducing headcount at San Francisco-based Genentech by merging the information technology departments of its pharmaceutical and diagnostics divisions. The company didn’t disclose how many people would be losing jobs as a result of the consolidation.

The company previously merged all of its human resources functions and roughly 20% of HR personnel lost their jobs—although most were able to find new jobs within Roche.

A Roche spokeswoman added that the company will continue unifying its communication processes in an attempt to further reduce the size of its workforce.

Expect more announcements from Roche in the coming months.

Until next time...

Good Luck and Good Job Hunting!!!!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Over the past ten years or so, pundits have been warning that the US is losing its competitive edge and that it is no longer the world’s leading nation when it comes to innovation in science and technology. Measuring national competitiveness and innovation is very tricky business and until now, most of evidence to support these claims has been anecdotal. According to an article in today’s New York Times, a report by the Information Technology and Innovation Foundation suggests that the US ranked sixth among 40 countries and regions based on 16 indicators that measure innovation and competitiveness including venture capital investment, numbers of per capita researchers, research spending and educational achievement. 

While the results of Foundation study may be troubling (if you are a US citizen), another recent study conducted by the World Economic Forum found that America ranked first in innovation and global competition. However the forum’s report was based entirely on opinion survey data.  Like the forum report, a study conducted by the Rand Corporation last year, also found that “the US was not in any imminent danger of losing its competitive advantage in science and technology.” The use of the word “imminent” is perhaps the most telling aspect of the Rand Corporation’s conclusion about American competitiveness.

The US lost ground to much smaller countries like Sweden, Finland, Taiwan, Singapore and also to one of it's main competitors, China.  Unlike the US, all of these countries are pursuing government-sponsored initiatives designed to promote innovation and global competitiveness. Some of the elements of these initiatives include education, workforce development training, intellectual property protection and immigration. Surprisingly, results from the foundation report (adjusted for population and size of each economy) showed that the US ranked sixth in venture capital investment (Sweden was first); fifth in corporate research and development spending (Japan was number one) and fourth in the number of science and technology researchers (again Sweden was first). Over all, Singapore ranked first in innovation and competitiveness. As some of you may know, Singapore--for the past 10 years--has heavily invested in the life sciences and has managed to induce some of world’s leading bioscientists to immigrate.

One of the main recommendations of the report suggests that the federal government ought to follow the lead of the individual states, many of which developed state government-sponsored programs designed to attract investment, talent and improve the work force skills of  local would be employees. Further, the report specifically recommends that the federal government offers tax breaks and incentives to induce American companies to innovate at home rather than outsource R&D activities abroad. Some of these incentives could include tax research tax credits  and increased federal funding or corporate tax breaks for workforce development programs.

Finally, one of the most shocking statistics that I heard in President Obama’s speech to Congress last evening was that 50% of American students drop out of high school and over 50% of college students never complete their education. This begs the question: How can America expect to remain competitive when a majority of its population is less educated than the rest of the developed world? 

A past commitment to education is what propelled the US to become a world leader in innovation and competitiveness.  To regain its past status as an innovator, the US must overhaul and vastly improve is primary, secondary and post secondary education system. This is something that cannot wait—the future of American depends on it!

Until next time...

Good Luck and Good Job Hunting ( give teaching a shot)

• Email This
• Print
• Comments (1)
• Trackbacks
• Share Link

 Merck announced today that as part of its ongoing restructuring plan to cut costs it will eliminate approximately 7,200 positions — 6,800 active employees and 400 vacancies — across all areas of the Company worldwide by the end of 2011.  This amounts to a 12 percent reduction in the company’s workforce. About 40 percent of the total reductions will occur in the United States.  To streamline management layers across the Company, Merck will reduce its total number of senior and mid-level executives by approximately 25 percent.  These positions are in addition to the 10,400 positions.  As of Sept. 30, Merck has approximately 56,700 employees. In addition to the layoffs, Merck will close three research facilities; one in Tsukuba, Japan; another in Pomezia, Italy and one in Seattle Washington by the end of 2009.

Merck expects the 2008 cutbacks to save the company $3.8 billion to $4.2 billion over the next five years. BioJobBlog reported several weeks ago that Merck had been quietly laying off employees since September. I suspect that today’s announcement comes as no surprise to employees who still work at the Company.

New Jersey once dubbed “America’s medicine chest” is starting to look less full!

Until next time…

Good Luck and Good Job Hunting

• Email This
• Print
• Comments
• Trackbacks
• Share Link

On the heels of yesterday’s announcement that it wants to buy Genentech, Roche, in a surprise move, announced today that it will move its Nutley, NJ-based US corporate headquarters to California. According to a report, research and development activities in oncology and metabolism at the Nutley site will be expanded. However, the company will consolidate all Nutley-based finance and information-technology operations and close manufacturing facilities on the site by 2010. It is not clear how many of Roche’s 3,240 New Jersey employees will be affected by the proposed move to South San Francisco. Suffice it to say, more than a few Roche employees are likely to lose their jobs after the company’s headquarters heads west.

Once dubbed the”nation's medicine chest”, New Jersey has steadily been losing pharmaceutical jobs since 1990 when 20% of all US pharmaceutical jobs were in NJ—at present 13.7% of  American pharmaceutical jobs reside in NJ. It has been a long, slow burn for the pharmaceutical and biotechnology workforce in the Garden State.

The Roche announcement comes as several other New Jersey drug makers, including Schering-Plough and Johnson & Johnson's Ortho Biotech unit, have been laying off workers because of the economic downturn and tough times in the industry. It also comes several days after Barr Pharmaceuticals, headquartered in Montvale, announced that it is being acquired for $7.5 billion by Israeli generics giant Teva.  

The growing scarcity of pharmaceutical and biotechnology jobs coupled with the highest property taxes in the US may cause a mass migration from the state. Not that there is anything wrong with that!!!!!!

Until next time….

Good Luck and Good Job Hunting!!!!!

• Email This
• Print
• Comments (2)
• Trackbacks
• Share Link

Siemens, the German conglomerate that manufactures everything from locomotives to medical imaging devices, officially announced on Tuesday that it will be sacking 4% of it workforce or 16,750 employees. Although the company didn’t specify where all of the cut would be taking place—it is a global workforce reduction—a company spokesperson did indicate that 1,500 administrative jobs in its healthcare division would be eliminated and most of those jobs are in the US. Many of these cuts will likely take place in the tri-state area (New York, New Jersey and Pennsylvania)—not welcome news for the already battered pharmaceutical and biotechnology industries in the region.

While the cuts seem pretty substantial to most people (especially those Siemens employees who are losing their jobs) one company executive quipped “If you have 400,000 people on your payroll, cutting 17,000 is not that big a deal” — only if you aren’t one of the people who is losing a job.

Until next time….

Good Luck and Good Job Hunting!!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

Cambridge, MA-based Alkermes announced today that it is restructuring its operations following the termination by Eli Lilly and Company of its inhalable AIR Insulin program (Alkermes manufactured the inhaler delivery device). The company is reducing its workforce by approximately 150 employees and closing its AIR commercial manufacturing facility in Chelsea, MA. The company is taking these actions based on its current expectations of the financial impact of Lilly's termination of the AIR Insulin program.

The job cuts, effective this week, represent almost 18% of Alkermes’ total workforce. Employees affected by the restructuring will be eligible for a severance package that includes severance pay, continuation of benefits and outplacement services. The company expects cost savings from the restructuring in the range of $15 million to $20 million in fiscal 2009.

In other news from across the pond, the trade group, the Association of the British Pharmaceutical Industry (ABPI), reported today that the UK pharmaceutical industry lost about 8.000 pharmaceutical jobs or about 10% of its workforce over the past three years. The ABPI asserts that there is a direct link between job cuts and changes to the British government’s pricing mechanisms for medicines. A spokesperson for the group said “Every time a new PPRS (Pharmaceutical Price Regulation Scheme) comes into force there is a decline in the number of jobs”. Not surprisingly, the group is urging the government to not make any changes in the PPRS.

The UK pharmaceutical workforce has taken a number of big hits of late– Pfizer recently closed a manufacturing plant in Kent, while British drug makers AstraZeneca and GlaxoSmithKline both announced substantial global job cuts many of which were located in Britain.

Until next time….

Good Luck and Good Job Hunting!!!!

• Email This
• Print
• Comments
• Trackbacks
• Share Link

 A report on the state of the Massachusetts biotechnology industry suggests that global competition and shortages of trained workers might cause the state to loss its reputation as one of the world’s top life sciences cluster. The report points out that there simply aren’t enough trained workers to meet the growing demand from Massachusetts-based biotechnology companies-both because of a lack of adequate training programs and lack of interest from students.  

To help to remedy the situation, the study recommended that more job training programs ought to be created at two- and four-year state colleges and that Massachusetts should do more to encourage students to pursue careers in the life sciences. As usual, the report recommended that math and science education should be improved at the K-12 levels. Other suggestions included setting up a “summer bio camp” and launching an unpaid bioscience internship program.

Unfortunately, this report, which was prepared by Boston-based Mass Insight Corp and McKinsey & Co and was likely very expensive, is almost identical to other studies published over the past decade about ongoing workforce shortages in the life sciences industry. Like its predecessors, it contains the same tired and unimaginative recommendations that others have proposed to solve bioscience labor shortages. To learn more about some creative solutions to avert life sciences workforce shortages click here.

Despite what the experts and pundits would have you believe, the etiology of the workforce shortages in the life sciences industry is easy to decipher. Put simply, most universities and colleges don’t believe that job training or career development should be part of their academic initiatives or educational missions. Likewise, companies don’t feel that education or training should fall within their purview–according to industry executives, college and professional school graduates ought to be sufficiently prepared to enter the workforce after they complete their education.

Because neither academia nor industry wants to assume responsibility (financial or otherwise) to prepare or train students for careers in the life sciences, it should come as no surprise that there are workforce shortages in this industry. Although a number of federally-funded biotraining programs were initiated in the late 1990s, these programs were poorly promoted and are incapable of sustaining themselves without government support. Paradoxically, there are many more innovative, industry-focused biotechnology and bioscience training programs at the high school level as compared with the undergraduate and graduate levels. I suspect that many professors in undergraduate and graduate life sciences departments are more concerned about their own research programs than about the careers of their students. Go figure………!!!!!

There will continue to be workforce shortages in the biotechnology, pharmaceutical and medical devices industry until either academia, industry or both claims ownership of bioscience training and career development.  I think that it time for academicians and industry professionals alike to put their heads together to solve this serious and ongoing problem. Failure to do so will result in the loss of America’s global dominance in the life sciences industry.

Until next time…

Good Luck and Good Job Hunting!!!!!!!!!!!

• Email This
• Print
• Comments (1)
• Trackbacks
• Share Link